9amHealth

About 9amHealth

9amHealth was founded in 2021 with a focused mission: making cardiometabolic care — the intersection of heart health, diabetes, and weight management — accessible, affordable, and clinically excellent through telehealth. Unlike platforms that treat weight loss as an isolated goal, 9amHealth approaches GLP-1 prescribing within the broader context of metabolic syndrome, addressing blood sugar, cholesterol, blood pressure, and weight as interconnected conditions. This clinical philosophy produces a more thorough treatment experience than most standalone weight loss services.

The platform prescribes both compounded and brand-name GLP-1 medications for diabetes and weight loss, with monthly costs ranging from $99-$299 depending on the medication and plan selected. Critically, 9amHealth accepts insurance, which can significantly reduce out-of-pocket costs for patients with qualifying coverage. The company has also partnered with Lilly Direct, Eli Lilly’s direct-to-patient pharmacy channel, giving patients streamlined access to brand-name tirzepatide (Zepbound/Mounjaro) at competitive pricing. This partnership signals pharmaceutical-level trust in 9amHealth’s clinical operations.

Clinical outcomes data from 9amHealth is compelling: the platform reports an average weight reduction of 17.6% among patients in its weight management program, a figure that rivals the results seen in clinical trials of brand-name semaglutide and tirzepatide. Every patient receives comprehensive lab testing, ongoing metabolic monitoring, and access to a registered dietitian for nutritional counseling. The care team includes board-certified endocrinologists and internists, not just general practitioners — a level of specialist oversight that distinguishes 9amHealth from most telehealth GLP-1 providers.

9amHealth holds an A rating with the Better Business Bureau, reflecting solid business practices and complaint resolution. The platform does not yet have a Trustpilot presence, so large-scale independent consumer review data is not available. However, the combination of published outcomes data, specialist-led care, and the Lilly Direct partnership provides a strong foundation of clinical credibility. Our editorial team was particularly impressed by the cardiometabolic focus, which ensures patients receive treatment for the root causes of metabolic disease rather than just the number on the scale.

The support level at 9amHealth is high, with regular provider check-ins, dietitian consultations, lab reviews, and messaging access to the care team. The platform is designed for patients who want comprehensive metabolic health management, not just a GLP-1 prescription. Pricing is transparent and competitive, especially for patients who can leverage insurance coverage or the Lilly Direct partnership. For patients seeking a clinically serious, outcomes-driven approach to GLP-1 therapy within a broader metabolic health framework, 9amHealth is one of the strongest options we have reviewed.

9amHealth GLP-1 Medications

At a Glance